These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 6295693)

  • 1. [Effects of suloctidil therapy on platelet function in patients with on obliterating arteriopathy of the lower limbs].
    Davì G; Pinto A; Novo S; Avellone G; Galati D; Mazzola A
    Clin Ter; 1982 Oct; 103(2):131-7. PubMed ID: 6295693
    [No Abstract]   [Full Text] [Related]  

  • 2. [Medium term treatment with suloctidil in obliterating arteriopathies of the lower limbs. Personal experience].
    Marongiu G; Dettori G; Gadeddu A; Noya G; Angius P; Biglioli P
    Minerva Cardioangiol; 1983; 31(7-8):407-10. PubMed ID: 6316206
    [No Abstract]   [Full Text] [Related]  

  • 3. [Behavior and significance of beta-thromboglobulin in chronic obliterating arteriopathy of the lower limbs. Preliminary research].
    Binaghi F; Valle E; Manconi E; Pitzus F
    Cardiologia; 1982 Nov; 27(11):1043-9. PubMed ID: 6085827
    [No Abstract]   [Full Text] [Related]  

  • 4. [Medical therapy of chronic obstructive arteriopathy of the lower extremities. A controlled clinical study of suloctidil versus xanthinol].
    Spinella G; Majorana M
    Clin Ter; 1983 Mar; 104(5):375-81. PubMed ID: 6303677
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.).
    Moriau M; Col-De Beys C; Pardonge E; Ferrant A
    Thromb Haemost; 1982 Feb; 47(1):27-31. PubMed ID: 6280332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the platelet component in chronic obliterating vascular disease of the lower limbs].
    Avellone G; Nova S; Gullotti D; Mandalà V
    Boll Soc Ital Cardiol; 1979; 24(2):135-41. PubMed ID: 548089
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hemorrheological survey in a group with arteriosclerotic vascular disease treated with suloctidil].
    Caimi G; Catania A; Frazzetta F; Capobianco D; Francavilla G; Romano A; Sarno A
    Ric Clin Lab; 1983; 13 Suppl 3():465-8. PubMed ID: 6324326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of proxazole on patients with obliterating arteriopathy of the lower limbs].
    Saponaro A; Russo R; Tomei F; Giordano M; Dragagna G; Barbato G
    Clin Ter; 1979 Dec; 91(6):585-92. PubMed ID: 544162
    [No Abstract]   [Full Text] [Related]  

  • 9. [Role of the blood platelets in the atherosclerotic process and clinical use of a new drug, Suloctidil, with anti-aggregating activity].
    Armani U; Piana A
    Arch Maragliano Patol Clin; 1979; 35(2):57-62. PubMed ID: 233645
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of suloctidil on platelet function in patients with shortened platelet survival time.
    Turpie AG; Gent M; deBoer AC; Giroux M; Kinch D; Butt R; Gunstensen J; Saerens E; Genton E
    Thromb Res; 1984 Aug; 35(4):397-406. PubMed ID: 6091290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Short-term heparin therapy in obliterating arteriopathies of the lower limbs].
    Arrigo F; Coglitore S; Giannetto M; Bramanti O; Barbera C; Consolo F
    Boll Soc Ital Cardiol; 1977; 22(3):273-82. PubMed ID: 617274
    [No Abstract]   [Full Text] [Related]  

  • 12. [Chronic senile cerebrovascular insufficiency. Effects of suloctidil and pentoxifylline on erythrocyte deformability].
    Pilla G; Ciaponi A; Migliavacca A; Bonora C
    Ric Clin Lab; 1983; 13 Suppl 3():459-64. PubMed ID: 6324325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of suloctidil on tomographically quantitated platelet accumulation in Dacron aortic grafts.
    Stratton JR; Ritchie JL
    Am J Cardiol; 1986 Jul; 58(1):152-6. PubMed ID: 3014851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies of suloctidil in experimental thrombosis in baboons.
    Hanson SR; Harker LA
    Thromb Haemost; 1985 Jun; 53(3):423-7. PubMed ID: 2996168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Suloctidil (sulocton) in the treatment of atherosclerotic neurasthenic syndromes].
    Prusiński A; Kotwica S; Niewodniczy A; Split W
    Wiad Lek; 1982 May; 35(3-4):201-5. PubMed ID: 6287740
    [No Abstract]   [Full Text] [Related]  

  • 16. [Platelet aggregation in obliterating arteriopathies of the lower limbs. Preliminary findings].
    Rossi M; Evangelisti L; Giusti C; Santoro G; Pentimone F; Camici M
    Minerva Cardioangiol; 1982 Jun; 30(6):329-33. PubMed ID: 7133421
    [No Abstract]   [Full Text] [Related]  

  • 17. [Behavior and meaning of beta-thromboglobulin in chronic obliterative arteriopathy of the lower extremities. Preliminary study].
    Binaghi F; Valle E; Manconi E; Pitzus F
    Cardiologia; 1982 Nov; 27(11):1043-9. PubMed ID: 6204655
    [No Abstract]   [Full Text] [Related]  

  • 18. [Comparative etiology of obliterating arteriopathy of the lower limbs and of coronary arteriopathy].
    Schwartz D; Lellouch J; Anguera G; Richard JL; Beaumont JL
    Rev Atheroscler; 1965; 7():Suppl 3:24-32. PubMed ID: 5885322
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs.
    Davì G; Pinto A; Francavilla G; Paterna S; Campisi D; Strano A
    Thromb Res; 1985 Oct; 40(2):275-81. PubMed ID: 2933846
    [No Abstract]   [Full Text] [Related]  

  • 20. [Evaluation of the clotting system and fibrinolysis after 1-stage novocaine parasciatic blockade in patients with obliterating atherosclerosis of the lower limbs].
    Kempf Z
    Przegl Lek; 1970 Sep; 26(9):735-7. PubMed ID: 5472570
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.